Cronos Group Inc. (CRON) stock
CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/306% below fair value
$3.41−0.04 (-1.16%)
Close on Nov 12, 2026Market cap $1.26BP/E 20.1Yield –
Cronos EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Cronos's EPS for the twelve months ending Sep 30, 2026 was $0.17, up 70.0% year over year. For fiscal 2025 it was -$0.02, down 118.2% from the year before. The highest annual figure on record is $3.33 in fiscal 2019.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.02 | -118.2% |
| FY2024 | Dec 31, 2024 | $0.11 | – |
| FY2023 | Dec 31, 2023 | -$0.19 | – |
| FY2022 | Dec 31, 2022 | -$0.45 | – |
| FY2021 | Dec 31, 2021 | -$1.07 | – |
| FY2020 | Dec 31, 2020 | -$0.21 | -106.3% |
| FY2019 | Dec 31, 2019 | $3.33 | – |
| FY2018 | Dec 31, 2018 | -$0.12 | – |
| FY2017 | Dec 31, 2017 | -$0.01 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.04 | -42.9% |
| Q2 FY2026 | Jun 30, 2026 | $0.09 | – |
| Q1 FY2026 | Mar 31, 2026 | $0.04 | +100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0.00 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0.07 | +250.0% |
| Q2 FY2025 | Jun 30, 2025 | -$0.10 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.02 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.11 | – |
| Q3 FY2024 | Sep 30, 2024 | $0.02 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.02 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.01 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.12 | – |
| Q3 FY2023 | Sep 30, 2023 | $0.00 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.02 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.05 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.21 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.10 | -147.6% |
| Q2 FY2022 | Jun 30, 2022 | -$0.05 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.09 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.36 | – |
| Q3 FY2021 | Sep 30, 2021 | $0.21 | +10.5% |
| Q2 FY2021 | Jun 30, 2021 | -$0.48 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.44 | -320.0% |
| Q4 FY2020 | Dec 31, 2020 | -$0.39 | -343.8% |
| Q3 FY2020 | Sep 30, 2020 | $0.19 | -88.3% |
| Q2 FY2020 | Jun 30, 2020 | -$0.31 | -293.8% |
| Q1 FY2020 | Mar 31, 2020 | $0.20 | -39.4% |
| Q4 FY2019 | Dec 31, 2019 | $0.16 | – |
| Q3 FY2019 | Sep 30, 2019 | $1.62 | – |
| Q2 FY2019 | Jun 30, 2019 | $0.16 | – |
| Q1 FY2019 | Mar 31, 2019 | $0.33 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.05 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.03 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.02 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.02 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?